FrancophonIA/ELRC3.0 huggingface dataset:
English: Oseltamivir carboxylate inhibits influenza A and B neuraminidases in vitro.
Maltese: Oseltamivir carboxylate jinibixxi neuraminidases tal-influwenza A u B in vitro.
English: Renal clearance (18.8 l/h) exceeds glomerular filtration rate (7.5 l/h) indicating that tubular secretion occurs in addition to glomerular filtration.
Maltese: It-tneħħija mill-kliewi (18.8 l/h) teċċedi r-rata ta' filtrazzjoni glomerulari (7.5 l/h) li jindika li sekrezzjoni tubulari sseħħ flimkien ma' filtrazzjoni glomerulari.
English: • methotrexate (used to treat e.g. rheumatoid arthritis)
Maltese: • methotrexate (jintuża biex jittratta eż. artrite rewmatika)
English: The pharmacist may compound a 6 mg/ml suspension from Ebilfumin 30 mg, 45 mg or 75 mg capsules using water containing 0.05 % w/v sodium benzoate added as a preservative.
Maltese: L-ispiżjar jista' jħallat suspensjoni ta' 6 mg/ml minn kapsuli Ebilfumin ta' 30 mg, 45 mg jew 75 mg bl-użu ta' ilma li għandu miżjud 0.05% w/v sodium benzoate bħala preservattiv.
English: Do not take Ebilfumin.
Maltese: Tieħux Ebilfumin.
English: • Mild to severe liver function disorders
Maltese: • Disturbi ħfief sa severi fil-funzjoni tal-fiwed
English: The NNT for the total paediatric population was 9 (95 % CI 7 - 24) and 8 (95 % CI 6, upper limit not estimable) in the whole population (ITT) and in paediatric contacts of infected index cases (ITTII), respectively.
Maltese: L-NNT għall-popolazzjoni pedjatrika totali kien ta' 9 (95 % CI 7 - 24) u 8 (95 % CI 6, limitu ta' fuq mhux stmat) fil-popolazzjoni kollha (ITT) u f'kuntatti pedjatriċi ta' każijiet indiċi infettati (ITTII), rispettivament.
English: The pharmacokinetics of oseltamivir in children and adolescents 12 years of age or older are similar to those in adults.
Maltese: Il-farmakokinetika ta' oseltamivir fi tfal u adoloxxenti b'età ta' 12-il sena u aktar hija simili għal dik fl-adulti.
English: Treating flu:
Maltese: Trattament talinfluwenza:
English: Ebilfumin 30 mg hard capsules Ebilfumin 45 mg hard capsules Ebilfumin 75 mg hard capsules
Maltese: Ebilfumin 30 mg kapsuli ibsin Ebilfumin 45mg kapsuli ibsin Ebilfumin 75mg kapsuli ibsin
English: A vaccine gives you antibodies against the virus.
Maltese: Tilqima tagħtik antikorpi kontra l-virus.
English: Preventing flu:
Maltese: Prevenzjoni talinfluwenza:
English: Data from 504 influenza B infected subjects were pooled across all studies for analysis.
Maltese: Data nġabret minn 504 individwi infettati bl-influwenza B minn fost l-istudji kollha sabiex tiġi analizzata.
English: See section 4.2 for information on paediatric use.
Maltese: 4.2 għal informazzjoni dwar l-użu pedjatriku.
English: Seasonal prophylaxis: Longer duration of seasonal prophylaxis up to 12 weeks has been evaluated in immunocompromised patients (see sections 4.4, 4.8 and 5.1).
Maltese: Tul ta' żmien itwal ta' profilassi staġjonali sa 12-il ġimgħa kien evalwat f'pazjenti immunokompromessi (ara sezzjonijiet 4.4, 4.8 u 5.1).
English: During oseltamivir treatment, rare events have been reported that include
Maltese: Waqt trattament b'oseltamivir kienu rrappurtati avvenimenti rari li jinkludu
English: No specific antidote is known.
Maltese: Mhux magħruf antidotu speċifiku.
English: Volume per dose 6 mg/ml
Maltese: 6 mg/ml
English: The study included solid organ transplant [SOT] patients, haematopoietic stem cell transplant [HSCT] patients, HIV positive patients with a CD4+ cell count <500 cells/mm3, patients on systemic immunosuppressive therapy, and those with haematological malignancy.
Maltese: L-istudju inkluda pazjenti bi trapjant ta' organu solidu [SOT - solid organ transplant], pazjenti bi trapjant ta' ċelluli staminali ematopoetiċi [HSCT - haematopoietic stem cell transplant], pazjenti pożittivi għall-HIV b'għadd ta' ċelluli CD4+ ta' <500 ċellula/mm3, pazjenti fuq terapija immunosoppressiva sistemika, u dawk b'tumur malinn ematoloġiku.
English: Ebilfumin is not a substitute for influenza vaccination.
Maltese: Ebilfumin mhux sostitut għat-tilqima kontra l-influwenza.
English: Ebilfumin hard capsules are bioequivalent formulations.
Maltese: Il-kapsuli ibsin ta' Ebilfumin huma sustanzi bioekwivalenti.
English: > 7 kg to 10 kg
Maltese: > 7 kg sa 10 kg
English: • Convulsion
Maltese: • Konvulżjonijiet
English: 18 mg
Maltese: 18mg darbtejn kuljum
English: 11 capsules (825 mg)
Maltese: 11-il kapsula (825 mg)
English: Adults and adolescents 13 and over Very common side effects
Maltese: Adulti u adoloxxenti minn 13-il sena 'l fuq Effetti sekondarji komuni ħafna
English: The overall safety profile of oseltamivir is based on data from 6049 adult/adolescent and 1473 paediatric patients treated with oseltamivir or placebo for influenza, and on data from 3990 adult/adolescent and 253 paediatric patients receiving oseltamivir or placebo/no treatment for the prophylaxis of influenza in clinical trials.
Maltese: Il-profil ta' sigurtà globali ta' oseltamivir huwa bbażat fuq data minn 6049 pazjent adult/adoloxxenti u 1473 pazjent pedjatriku ttrattati b'oseltamivir jew plaċebo għall-influwenza, u fuq data minn 3990 pazjent adult/adoloxxenti u 253 pazjent pedjatriku li rċevew oseltamivir jew plaċebo/l-ebda trattament għall-profilassi tal-influwenza fi studji kliniċi.
English: • Upper respiratory tract infections (inflammation of the nose, throat and sinuses)
Maltese: • Infezzjonijiet fl-apparat respiratorju ta' fuq (infjammazzjoni tal-imnieħer, griżmejn u sinusis)
English: Post-exposure prevention of influenza in infants less than 1 year of age during a pandemic:
Maltese: Prevenzjoni tal-influwenza wara espożizzjoni fi trabi ta' età inqas minn sena waqt pandemija:
English: • Teaspoon (5 ml spoon)
Maltese: • Kuċċarina (ta' 5 ml)
English: > 23 kg to 40 kg
Maltese: > 23 kg sa 40 kg
English: The binding of the oseltamivir carboxylate to human plasma protein is negligible (approximately 3 %).
Maltese: L-irbit ta' oseltamivir carboxylate mal-proteina tal-plażma umana huwa negliġibbli (madwar 3 %).
English: Since 2007 naturally occurring resistance associated with the H275Y mutation in seasonal H1N1 strains has been sporadically detected.
Maltese: Minn 2007 ġiet misjuba kultant mutazzjoni ta' H275Y assoċjata ma' reżistenza ta' okkorenza naturali f'razez staġjonali ta' H1N1.
English: The NNT in this study was 28 (95 % CI 24 - 50).
Maltese: L-NNT f'dan l-istudju kien ta' 28 (95 % CI 24 - 50).
English: Oseltamivir phosphate inhibits influenza virus infection and replication in vitro.
Maltese: Oseltamivir phosphate jinibixxi l-infezzjoni b'virus tal-influwenza u r-replikazzjoni in vitro.
English: [Only applicable for outer packaging:] PC: {number}
Maltese: [Applikabbli biss għall-pakkett ta' barra:]
English: It allows continued monitoring of the benefit/risk balance of the medicinal product.
Maltese: Dan jippermetti l-monitoraġġ kontinwu tal-bilanċ ta 'benefiċċju / riskju tal-prodott mediċinali.
English: Treatment: The recommended oral dose is 75 mg oseltamivir twice daily for 10 days for adults (see sections 4.4, 4.8 and 5.1).
Maltese: Għall-adulti d-doża orali rakkomandata hija ta' 75 mg oseltamivir darbtejn kuljum għal 10 ijiem (ara sezzjonijiet 4.4, 4.8 u 5.1).
English: • Stevens-Johnson syndrome and toxic epidermal necrolysis: complicated, possibly lifethreatening allergic reaction, severe inflammation of the outer and possibly inner skin, initially with fever, sore throat, and fatigue, skin rashes, leading to blisters, peeling, shedding of larger areas of skin, possible breathing difficulties and low blood pressure
Maltese: • Sindrome Stevens-Johnson u nekrolisi tossika tal-epidermide: reazzjoni allerġika ikkumplikata, b'possibbiltà ta' periklu għall-ħajja, infjammazzjoni severa tal-ġilda ta' barra u possibilment ta' ġewwa, inizjalment b'deni, uġigħ fil-griżmejn, u għeja, raxx fil-ġilda, li jwassal għal infafet, tqaxxir, telf ta' żoni akbar ta' ġilda, possibilment b'diffikultajiet fitteħid tan-nifs u pressjoni baxxa
English: • phenylbutazone (used to treat pain and inflammation)
Maltese: • phenylbutazone (jintuża biex jittratta uġigħ u infjammazzjoni)
English: 10 capsules
Maltese: 10 kapsuli ibsin
English: 20 capsules (600 mg)
Maltese: 20 kapsula (600 mg)
English: Eczema,
Maltese: Madankollu,
English: • Confusion, abnormal behaviour
Maltese: • Konfużjoni, mġiba mhux normali
English: Incidence of Oseltamivir Resistance in Clinical Studies Patient Population
Maltese: Inċidenza ta' Reżistenza għal Oseltamivir fi Studji Kliniċi
English: The pharmacy preparation should be preferred to home preparation.
Maltese: Il-preparazzjoni magħmula fl-ispiżerija għandha tkun ippreferuta minn preparazzjoni magħmula d-dar.
English: - Keep this leaflet.
Maltese: Popolazzjoni ta' Pazjenti
English: - Ebilfumin is indicated for post-exposure prevention of influenza in infants less than 1 year of age during a pandemic influenza outbreak (see section 5.2).
Maltese: - Ebilfumin huwa ndikat għall-prevenzjoni tal-influwenza wara espożizzjoni fi trabi b'età inqas minn sena waqt tifqigħa ta' influwenza pandemika (ara sezzjoni 5.2).
English: The available data indicates that the exposure following a 3 mg/kg dose in infants 012 months of age provides pro-drug and metabolite exposures anticipated to be efficacious with a safety profile comparable to that seen in older children and adults using the approved dose (see sections 4.1 and 4.2).
Maltese: Id-data disponibbli tindika li l-espożizzjoni ta' wara doża ta' 3 mg / kg fi trabi minn 0 - 12 xahar ta' età, turi li espożizzjoni għall-pro-droga u metaboliti hija mistennija li tkun effikaċi bi profil ta' sigurtà komparabbli ma' dik osservata fi tfal akbar u adulti li jużaw id-doża approvata (ara sezzjonijiet 4.1 u
English: 3 kg to 10+ kg
Maltese: 3 kg sa 10+kg
English: Treatment and prevention of influenza in adults and adolescents:
Maltese: It-trattament u l-prevenzjoni tal-influwenza fl-adulti u l-adoloxxenti:
English: > 30 to 60 (ml/min)
Maltese: > 30 sa 60 (ml/min)
English: > 15 kg to 23 kg
Maltese: > 15 kg sa 23 kg
English: 8 capsules (360 mg)
Maltese: 8 kapsuli (360 mg)
English: Dose of Ebilfumin Number of capsules
Maltese: Doża ta' Ebilfumin Numru ta' kapsuli
English: 3 mg per kg,
Maltese: 3 mg kull kg,
English: Yellow iron oxide (E172) Titanium dioxide (E171)
Maltese: Iron oxide isfar (E172) Titanium dioxide (E171)
English: In the overall treatment population, influenza infection was confirmed in 67 % (range 46 % to 74 %) of the recruited patients.
Maltese: Fil-popolazzjoni kollha li ngħatat it-trattament, l-infezzjoni tal influwenza ġiet ikkonfermata f'67 % (firxa minn 46 % sa 74 %) tal-pazjenti.
English: 25 capsules (750 mg)
Maltese: 25 kapsula (750 mg)
English: Gastrointestinal bleedings, Haemorrhagic colitis
Maltese: Fsada gastrointestinali, Kolite emorraġika
English: Treatment: The recommended treatment dose for infants 0 - 12 months of age is 3 mg/kg twice daily.
Maltese: Id-doża ta' trattament rrakkomandata għal trabi ta' 0 - 12-il xahar t'età hija 3 mg / kg darbtejn kuljum .
English: The percentage of patients reporting adverse events was lower in the standard dose group compared to the double dose group (49.0% vs 59.4 %, respectively) (See section 5.1).
Maltese: Ilperċentwali ta' pazjenti li rrappurtaw avvenimenti avversi kien aktar baxx fil-grupp ta' doża standard meta mqabbel mal-grupp ta' doża doppja (49.0% vs 59.4%, rispettivament) (Ara sezzjoni 5.1).
English: Confusion, Delusions, Delirium, Hallucination, Nightmares, Self-injury
Maltese: Ansjetà, Konfużjoni, Delużjonijiet, Delirju, Alluċinazzjoni, Inkubi, Ħsara lil persuna nnifisha
English: No clinical studies of prophylaxis in infants aged <1 have been performed.
Maltese: Ma sarux studji kliniċi ta' profilassi fi trabi ta' età < sena.
English: Read the package leaflet before use.
Maltese: Ebilfumin tista' tiġi ppreparata id-dar.
English: Oseltamivir reduced the time to alleviation of all symptoms by 0.7 days (95 % CI 0.1 - 1.6 days; p = 0.022) and the duration of fever (≥ 37.8 °C), cough and coryza by one day (95 % CI 0.4 - 1.7 days; p < 0.001) compared to placebo.
Maltese: Oseltamivir naqqas iż-żmien li damu biex ittaffew is-sintomi kollha b'0.7 ta' jum (95 % CI 0.1 - 1.6 jiem; p = 0.022) u l-perijodu bid-deni (≥ 37.8 °C), bis-sogħla u bil-koriża b'jum (95 % CI 0.4 - 1.7 jiem; p < 0.001), imqabbel mal-plaċebo.
English: Table 2 Adverse reactions in studies investigating oseltamivir for treatment and prevention of influenza in children (age/weight-based dosing [30 mg to 75 mg o.d.]) System Organ Class (SOC)
Maltese: Tabella 2 Reazzjonijiet avversi fi studji li nvestigaw oseltamivir għat-trattament u lprevenzjoni tal-influwenza fit-tfal (dożaġġ ibbażat fuq l-età/piż [30 mg sa 75 mg o.d.])
English: How to take Ebilfumin
Maltese: Doża ta' Ebilfumin
English: Home preparation
Maltese: Preparazzjoni d-dar
English: At 500 mg/kg, no adverse reactions were seen, including upon chronic treatment (500 mg/kg/day administered from 7 to 21 days post partum).
Maltese: Ma kienux osservati reazzjonijiet avversi b'500 mg/kg, inkluż waqt trattament kroniku (500 mg/kg/kuljum mogħtija minn 7 sa 21 ġurnata wara t-twelid).
English: The active metabolite is eliminated entirely by renal excretion.
Maltese: Dan ma jkomplix jiġi metabolizzat u jiġi eliminat fl-awrina.
English: Influenza was confirmed in 163 out of 377 index cases.
Maltese: L-influwenza ġiet ikkonfermata f'163 mit-377 każ indiċi.
English: Capsule size: 2.
Maltese: Daqs tal-kapsuli: 2.
English: The following serious adverse reactions have been rarely reported since oseltamivir has been marketed: Anaphylactic and anaphylactoid reactions, hepatic disorders (fulminant hepatitis, hepatic function disorder and jaundice), angioneurotic oedema, Stevens-Johnson syndrome and toxic epidermal necrolysis, gastrointestinal bleeding and neuropsychiatric disorders.
Maltese: Reazzjonijiet anafilattiċi u anafilaktojdi, disturbi tal-fwied (epatite fulminanti, disturb fil-funzjoni talfwied u suffejra), edima anġjonewrotika, sindrome Stevens-Johnson u nekrolisi tossika tal-epidermide, fsada gastro-intestinali u disturbi newropsikjatriċi.
English: Abnormal behaviour, Anxiety,
Maltese: Reazzjonijiet anafilattiċi,
English: 60 mg
Maltese: 60 mg darbtejn kuljum
English: In a double blind study for the treatment of influenza, a total of 199 adult immunocompromised patients (evaluable for safety) were randomized to receive oseltamivir for 10 days: 98 patients received the standard dose (75 mg twice daily) and 101 patients received the double dose (150 mg twice daily).
Maltese: Pazjenti immunokompromessi Fi studju double-blind dwar it-trattament tal-influwenza, total ta' 199 pazjent adult immunokompromess (li setgħu jiġu evalwati għas-sigurtà) kienu randomised biex jirċievu oseltamivir għal 10 ijiem: 98 pazjent irċevew id-doża standard (75 mg darbtejn kuljum) u 101 pazjent irċevew id doża doppja (150 mg darbtejn kuljum).
English: 23 to 40 kg
Maltese: 23 sa 40 kg
English: 27 mg
Maltese: 27mg darbtejn kuljum
English: 8 capsules (600 mg)
Maltese: 8 kapsuli (600 mg)
English: Stir the mixture well.
Maltese: Livell ta' koxjenza mibdul,
English: 45 mg
Maltese: Ebilfumin 45 mg
English: Pharmacotherapeutic group: Antivirals for systemic use, neuraminidase inhibitors, ATC code: J05AH02
Maltese: Antivirali għall-użu sistemiku, inibituri ta' neuraminidase Kodiċi ATC:
English: Population pharmacokinetic analysis indicates that treatment of adult immunocompromised patients with oseltamivir (as described in Section 4.2.
Maltese: L-analiżi tal-farmakokinetika tal-popolazzjoni tindika li t-trattament ta' pazjenti adulti immunokompromessi b'oseltamivir (kif deskritt fis-Sezzjoni 4.2.
English: 18 capsules (540 mg)
Maltese: 18-il kapsula (540 mg)
English: Severe renal impairment
Maltese: Indeboliment renali sever
English: oseltamivir significantly reduced the incidence of specified lower respiratory tract complications (mainly bronchitis) treated with antibiotics from 19 % (52/268) in the placebo group to 12 % (29/250) in the oseltamivir treated population (p = 0.0156).
Maltese: kumplikazzjonijiet speċifikati fil-parti t'isfel tal-passaġġ respiratorju (prinċiparjament bronkite) li ġew ittrattati bl-antibijotiċi minn 19 % (52/268) fil-grupp li ngħata l-plaċebo għal 12 % (29/250) fil popolazzjoni ttrattati b'oseltamivir (p = 0.0156).
English: Clinical studies: The risk of emergence of influenza viruses with reduced susceptibility or frank resistance to oseltamivir has been examined during Roche-sponsored clinical studies.
Maltese: Studji kliniċi: Ir-riskju ta' żvilupp ta' virusis tal-influwenza b'suxxettibilità mnaqqsa jew b'reżistenza ċara għal oseltamivir kien eżaminat waqt studji kliniċi sponsorjati minn Roche.
English: PVC/PE/PVdC/Al blisters or HDPE containers with LDPE lid (and a desiccant).
Maltese: In-natura tal-kontenitur u ta' dak li hemm ġo fih (PVC/PE/PVDC, issiġillat b'fojl tal-aluminju jew kontenituri HDPE b'għatu LDPE (u dessikant).
English: By day 6 (the last day of treatment) FEV1 had increased by 10.8 % in the oseltamivir treated group compared to 4.7 % on placebo (p = 0.0148) in this population.
Maltese: Sas-6 jum (l-aħħar jum tat-trattament), l-FEV1 kien żdied b'10.8 % filgrupp ittrattat b'oseltamivir mqabbel ma' 4.7 % fil-grupp tal-plaċebo (p = 0.0148) f'din il-popolazzjoni.
English: A total of 158 children received the recommended dose of oseltamivir once daily in a post-exposure prophylaxis study in households (n = 99), a 6-week paediatric seasonal prophylaxis study (n = 49) and a 12week paediatric seasonal prophylaxis study in immunocompromised subjects (n = 10).
Maltese: Total ta' 158 tifel u tifla rċevew id-doża rrakkomandata ta' oseltamivir darba kuljum fi studju dwar il-profilassi wara espożizzjoni fi djar (n = 99), fi studju pedjatriku dwar profilassi talistaġun li dam 6 ġimgħat (n = 49) u fi studju pedjatriku dwar profilassi tal-istaġun li dam 12-il ġimgħa f'individwi immunokompromessi (n = 10).
English: Extrapolation of the animal data provides estimates of 0.01 mg/day and 0.3 mg/day for the respective compounds.
Maltese: Estrapolazzjoni ta' data dwar l-annimali twassal għal stimi ta' 0.01 mg/jum u 0.3 mg/jum rispettivament għaż-żewġ sustanzi rispettivi.
English: True influenza infection only occurs during annual outbreaks (epidemics) when flu viruses are spreading in the local community.
Maltese: Infezzjoni proprja tal-influwenza sseħħ biss waqt li jkun hemm tifqigħa annwali (epidemija) meta l viruses tal-influwenza jkunu qed jinfirxu fil-komunità lokali.
English: alternative capsule strength*
Maltese: Determinazzjoni talFenotip*
English: Influenza is associated with adverse pregnancy and foetal outcomes, with a risk of major congenital malformations, including congenital heart defects.
Maltese: Tqala L-influwenza hija assoċjata ma' riżultati avversi fit-tqala u fuq il-fetu, b'riskju ta' malformazzjonijiet konġenitali maġġuri, inklużi difetti konġenitali fil-qalb.
English: Yellow iron oxide (E172) Titanium dioxide (E171) Body:
Maltese: Iron oxide isfar (E172) Titanium dioxide (E171) Titanium dioxide (E171)
English: Safety information available on oseltamivir administered for treatment of influenza in infants less than one year of age from prospective and retrospective observational studies (comprising together more than 2,400 infants of that age class), epidemiological databases research and postmarketing reports suggest that the safety profile in infants less than one year of age is similar to the established safety profile of children aged one year and older.
Maltese: Informazzjoni dwar is-sigurtà disponibbli dwar oseltamivir mogħti għat-trattament tal-influwenza fi trabi b'età inqas minn sena minn studji ta' osservazzjoni prospettivi u retrospettivi (li flimkien kienu jinkludu aktar minn 2,400 tarbija ta' din il-klassi ta' età), riċerka fid-databażi epidemjoloġiċi u rapporti ta' wara t-tqegħid fis-suq, tissuġġerixxi li l-profil ta' sigurtà fi trabi b'età inqas minn sena huwa simili għall-profil ta' sigurtà stabbilit fi tfal b'età minn sena 'l fuq.
English: (nearest)
Maltese: ijiem)
English: 30 mg
Maltese: Ebilfumin 30 mg
English: Developing oseltamivir-resistant virus during treatment was more frequent in children than adults, ranging from less than 1% in adults to 18% in infants aged below 1 year.
Maltese: inqas minn 1% fl-adulti għal 18% fi tfal ta' inqas minn sena eta.
English: Oseltamivir given orally inhibits influenza A and B virus replication and pathogenicity in vivo in animal models of influenza infection at antiviral exposures similar to that achieved in man with 75 mg twice daily.
Maltese: Oseltamivir mogħti mill-ħalq jinibixxi r-replikazzjoni u l-patoġeniċità tal-virus tal-influwenza A u B in vivo f'mudelli ta' annimali b'infezzjoni tal-influwenza b'espożizzjonijiet antivirali simili għal dik miksuba fil-bniedem b'75 mg darbtejn kuljum.
English: The mean volume of distribution at steady state of the oseltamivir carboxylate is approximately 23 litres in humans, a volume equivalent to extracellular body fluid.
Maltese: Distribuzzjoni Il-volum medju tad-distribuzzjoni ta' oseltamivir carboxylate fi stat fiss huwa ta' madwar 23 litru fil bnedmin, liema volum huwa ekwivalenti għall-fluwidu ekstraċellulari tal-ġisem.
English: 15 mg
Maltese: 15mg darbtejn kuljum
English: 15 to 23 kg
Maltese: 15 sa 23 kg
English: Pharmacy compounded 6 mg/ml suspension prepared from capsules
Maltese: Suspensjoni ta' 6 mg/ml imħallta fl-ispiżerija ppreparata minn kapsuli
English: (may affect up to 1 in 1,000 people)
Maltese: (jistgħu jaffettwaw sa persuna waħda minn kull 1,000)
English: 6 capsules (450 mg)
Maltese: 6 kapsuli (450 mg)
English: 75 mg
Maltese: Ebilfumin 75 mg
English: NN: {number}
Maltese: • Imqass jaqta'
English: Pain
Maltese: Piż
English: Pharmacokinetic properties of oseltamivir, such as low protein binding and metabolism independent of the CYP450 and glucuronidase systems (see section 5.2), suggest that clinically significant drug interactions via these mechanisms are unlikely.
Maltese: Interazzjoni ma' prodotti mediċinali oħra u forom oħra ta' interazzjoni Proprjetajiet farmakokinetiċi ta' oseltamivir, bħal-livell baxx ta' irbit mal-proteini u metaboliżmu indipendenti minn CYP450 u mis-sistemi ta' glucuronidase (ara sezzjoni 5.2), jissuġerixxu li interazzjonijiet klinikament sinifikanti bejn il-mediċini permezz ta' dawn il-mekkaniżmi huma improbabbli.
English: An overall higher incidence of oseltamivir-resistance was observed in adult immunocompromised patients treated with standard dose or double dose of oseltamivir for a duration of 10 days [14.9% (10/67) in standard dose group and 2.8% (2/71) in double dose group], compared to data from studies with oseltamivir-treated otherwise healthy adult patients.
Maltese: Inċidenza globalment ogħla ta' reżistenza għal oseltamivir kienet osservata f'pazjenti adulti immunokompromessi ttrattati b'doża standard jew doża doppja ta' oseltamivir għal tul ta' żmien ta' 10 ijiem [14.9% (10/67) fi grupp ta' doża standard u 2.8% (2/71) fi grupp ta' doża doppja], meta mqabbla ma' data minn studji b'pazjenti adulti li minbarra l-influwenza kienu f'saħħithom li ġew ittrattati b'oseltamivir.
English: Capsule shell Gelatin
Maltese: Qoxra tal-kapsulaGelatin
English: Dispenser size to use (grading 0.1 ml)
Maltese: (gradazzjoni ta' 0.1 ml)
English: Clinical and surveillance data: Natural mutations associated with reduced susceptibility to oseltamivir in vitro have been detected in influenza A and B viruses isolated from patients without exposure to oseltamivir.
Maltese: Data klinika u ta' sorveljanza: Mutazzjonijiet naturali assoċjati ma' suxxettibilità mnaqqsa għal oseltamivir in vitro instabu f'virusis tal-influwenza A u B iżolati minn pazjenti li ma kellhomx esponiment għal oseltamivir.
English: > 10 to 30 (ml/min)
Maltese: > 10 sa 30 (ml/min)
English: Use the larger dispenser to draw up 12.5 ml water.
Maltese: Uża d-dispenser il-kbir biex tiġbed 12.5 ml ilma.
English: Table 2 shows the most frequently reported ARs from paediatric clinical trials.
Maltese: Tabella 2 turi l-ARs irrappurtata bl-aktar mod frekwenti minn studji kliniċi fit-tfal.
English: 10 kg to 15 kg
Maltese: 10 kg sa 15-il kg
English: Prevention during an influenza epidemic in the community: Prevention during an influenza epidemic has not been studied in children 0-12 months of age.
Maltese: Prevenzjoni waqt influwenza pandemika fil-komunita': Prevenzjoni waqt influwenza pandemika għadu ma ġiex studjat fuq tfal ta' età 0 - 12-il xahar.